Reports say UK health officials are preparing to approve a daily weight-loss tablet developed by Novo Nordisk that is referred to as the “Wegovy Pill.” Multiple accounts cite sources close to the company suggesting the decision could be made within days. The tablet is described as a form of the medication Wegovy, currently known for weight-loss treatment delivered by injection, and the reporting indicates the pill may be positioned as a cheaper alternative to injections. The articles do not provide details from regulators themselves, nor do they specify pricing, eligibility criteria, or clinical data in the supplied text. They frame the approval as an expected next step, but stop short of confirming the timing or cost through an official announcement. Overall, the available information centers on an anticipated imminent UK regulatory decision and the possibility that the tablet could offer a lower-cost option compared with the injected formulation.